Warning: Creating default object from empty value in /home/altaywgm/public_html/wp-content/plugins/gaviasframework/redux/redux-framework/inc/class.redux_filesystem.php on line 29
New Indication: Hodgkin Lymphoma - Altai Oncology
  1. Home /
    2. Altai Protocol Library /
  2. New Indication: Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Indication: Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma

New Indication: Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma
Study:
  • Multicenter, non-randomized, phase 2trial
  • Relapsed or refractory classic Hodgkin lymphoma
  • Pembrolizumab + ICE (n=37)
Efficacy:
  • CRR: 86.5% [32 of 37 pts]
  • ORR: 97.3% [36 of 37 pts]
  • 2-year PFS: 87.2% [77.5-98.3]
  • 2-year OS: 95.1% [88.8%-100%]
Safety:
  • Grade≥3AEs: cytopenias, elevated AST/ALT, hyponatremia, hypophosphatemia, and fatigue.

JAMA Oncol, 2023, 16 MAR

Bryan J. Locke et al. Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial

http://doi.org/10.1001/jamaoncol.2022.7975

Reviewed by Elvin CHALABİYEV, MD on APR 17, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More